Although the critical role of Myc in regulating glucose metabolism in tumor and T cells (18, 30) is well-studied and Brd4 inhibitors are broadly applied in HIV-1 latency reversal and cancer therapy (31–36), it is unclear whether Brd4 inhibition affects CD8+ T-cell responses. The gene discussed is BRD4; the disease is neoplasm.